Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356813 | 1.00 | CYP19A1 (0.36) | CYP19A1GRM2GRM3TSHRNPSR1 | |
| SCHEMBL1325877 | 1.00 | CYP19A1 (0.36) | CYP19A1GRM2GRM3TSHRNPSR1 | |
| SCHEMBL1323798 | 0.71 | POLB (0.46) | CYP19A1TSHRNPSR1 | |
| SCHEMBL498176 | 0.71 | POLB (0.46) | CYP19A1TSHRNPSR1 | |
| SCHEMBL560921 | 0.71 | POLB (0.46) | CYP19A1TSHRNPSR1 | |
| SCHEMBL13090519 | 0.70 | MAPT (0.42) | — | |
| Hydrochloric Acid SCHEMBL560903 | 0.70 | POLB (0.45) | CYP19A1TSHRNPSR1 | |
| Hydrochloric Acid SCHEMBL560902 | 0.70 | POLB (0.45) | CYP19A1TSHRNPSR1 | |
| SCHEMBL4637001 | 0.69 | — | — | |
| SCHEMBL1324255 | 0.68 | TSHR (0.31) | CYP19A1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415487-B2 | Process for preparing (3R)-2′-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-A]pyrazine]-1′,2,3′,5(2H′)-tetraone | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8415487-B2 | Process for preparing (3R)-2′-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-A]pyrazine]-1′,2,3′,5(2H′)-tetraone | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8389742-B2 | 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20120010405-A1 | OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | TANAKA DAISUKE (JP) | 2012-01-12 | — | — | US | disclosed |
| US-8058456-B2 | Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-8058456-B2 | Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-8058456-B2 | Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-8003808-B2 | 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20110201807-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | TANAKA DAISUKE | 2011-08-18 | — | — | US | disclosed |
| US-20090286980-A1 | OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286980-A1 | OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090253917-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253917-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | SLC5A1, TERT, CBR3 | CYP19A1 3751/4885GRM2 4178/4885GRM3 2551/4885 |
| US-20090286980-A1 | OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | REN, GPR119, RANBP1 | CYP19A1 2942/4885GRM2 3574/4885GRM3 2414/4885 |
| US-20120010405-A1 | OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | REN, GPR119, RANBP1 | CYP19A1 2942/4885GRM2 3574/4885GRM3 2414/4885 |
| US-20110201807-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | CBR3, TERT, NOX4 | CYP19A1 3717/4885GRM2 4477/4885GRM3 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.